Otros idiomas RAPT Therapeutics, Inc.

Acciones

RAPT

US75382E1091

Tiempo real estimado Cboe BZX Otros sitios de cotización 19:22:05 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
7,79 ^USD	-1,14 %		-3,06 %	-68,79 %

09/04	RAPT Therapeutics anuncia resultados prometedores del ensayo de fase 2 de tivumecirnon en combinación con inmunoterapia anti-PD-1 en pacientes con cáncer de cabeza y cuello experimentados en IPC	CI
27/03	RAPT THERAPEUTICS, INC. : JPMorgan Chase se mantiene neutral, sin recomendación.	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index	18/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	11/03
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07/03
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07/03
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05/03
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	03/03
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	26/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
RAPT Therapeutics Shares Decline Following UBS Downgrade	22/02
North American Morning Briefing : Nvidia Ignites -2-	22/02
North American Morning Briefing : Stock Futures -2-	21/02
Sector Update: Health Care Stocks Lower Late Afternoon	20/02
Top Midday Decliners	20/02
RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold	20/02
Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event	20/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas RAPT Therapeutics, Inc.

Acciones

RAPT

US75382E1091

Otros idiomas

Filtros